Stempeutics signed a co-development agreement with Alkem
for its stem cell therapy product Stempeucel® for treating Osteoarthritis of the knee
Stempeutics signed a co-development agreement with Cipla
for its stem cell therapy product Stempeucel® for treating Critical Limb Ischemia
DCGI gives limited approval to market
FIRST allogeneic cell therapy product in India
Stempeutics Published CLI Phase 1
(in Journal of Translational Medicine) and Phase 2 study (in Stem Cells Translational Medicine)outcomes
Stempeutics Published OA Phase 2
study outcomes (in Arthritis Research & Therapy)Stempeutics received Phase 4 PMS study approval for CLI due to Buerger's
Stempeutics received Phase 3
approval for CLI due to atherosclerosis
Stempeutics received Form 28
commercial manufacturing approval for its Manipal GMP facility
Stempeutics receives Advanced Therapy Medicinal Product (ATMP)
classification from European Medicines Agency (EMA) for its novel stem cell drug "Stempeucel
Stempeutics receives US process patent (8,956,862)
for its novel stem cell drug "Stempeucel
Stempeutics gets stem cell patent in China
(Chinese Application number: CN201080053627) for its novel stem cell drug "Stempeucel
Stempeutics published the novelty of Stempeutron medical device
in the international journal "Stem Cells International"
Stempeutics partners with Global Consortium of cell therapy companies seeking European Union funding to combat Coronavirus Infections in Europe.
Stempeutics India signs an agreement with Novumcella Japan for development cooperation of Stempeucel® product for the Japanese market to treat Critical Limb Ischemia due to Buerger’s Disease.
US patent office issued notification to grant Patent to Stempeutics for its innovative stem cell drug “Stempeucel” for treating Critical Limb Ischemia (CLI).
CDSCO approves First “Made in India” novel Cell Therapy product “Stempeucel®” for commercial use for treating Critical Limb Ischemia.